
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
When a Division of Dermatology in Wright State's College of Medicine placed a newspaper ad to recruit volunteers for a tattoo-removal study, more than 100 people responded.